— Our team
MEet our dedicated team of scientists and researchers
Pedro Correa de Sampaio, PHD
Co-founder and CEO
Tumour microenvironment expert with over 12 years of research experience in top institutions including CRUK Cambridge Institute and MD Anderson Cancer Center. Authored multiple publications in immunooncology and contributed to development of innovative IO cell therapies at Triumvira Immunologics.
Annelise Soulier, PhD
Co-founder and CSO
Expert in molecular biology, microbiology and bacterial engineering. Formerly at Prokarium, with over 7 years experience in the engineering and development of bacterial therapeutic products for different disease indications. Co-inventor of patented engineered live biotherapeutics currently in clinical trials.
Keith Blundy, PhD
Director and Chairperson
Former Chief Executive Officer of Cancer Research Technology and STORM Therapeutics, with experience in strategy & licensing, drug development and venture capital fund raising. Formerly a director of KuDOS Pharmaceuticals Ltd, Mission Therapeutics, and Inivata Ltd.
Laura Fletcher, PHD
Director and Business Development Advisor
Business development professional with proven success in oncology commercial deals (including licences, alliances, and spin outs). Formerly at Cancer Research UK, responsible for leading outlicensing deals with Pharma partners such as AstraZeneca, Janssen Biotech and Ono Pharma.
Udo Wegmann
Principal Scientist
Research backed by leading scientific partners
Real therapeutic breakthroughs come when likeminded innovators work together to drive patient benefits. Our collaborative programmes with leading academics in synbio and immunology are integral to the core of our technology. We are backed by visionary investors who support us in our vision to enable therapeutic efficacy through next generation engineered live biotherapeutics.